What is an indication for milrinone?

A. Depression: Montelukast has been associated with neuropsychiatric effects, including depression, anxiety, and suicidal thoughts. Clients should be instructed to report mood changes promptly to the healthcare provider to ensure early intervention and medication safety.

B. Blurred vision: Blurred vision is not a common adverse effect of montelukast. While any new visual changes should be evaluated, it is not the primary concern related to this medication.

C. Palpitations: Palpitations are not typically linked to montelukast therapy. Cardiovascular symptoms should still be monitored if present, but they are not the main adverse effect prompting urgent reporting.

D. Constipation: Constipation is generally mild and uncommon with montelukast. It does not require immediate reporting unless severe or persistent, making it a lower-priority adverse effect compared to neuropsychiatric symptoms.

A. Seizure: Seizures are not a common manifestation of hydralazine toxicity. While severe hypotension could contribute to CNS symptoms, seizures are not a typical or expected clinical finding with this medication.

B. Hypertension: Hydralazine is a direct vasodilator used to lower blood pressure. Hypertension is not associated with hydralazine toxicity; instead, excessive hypotension may occur if the drug effect is too strong.

C. Tachycardia: Tachycardia is a common clinical finding associated with hydralazine toxicity. The vasodilation caused by hydralazine can lead to reflex sympathetic stimulation, resulting in an increased heart rate as the body attempts to maintain cardiac output and blood pressure.

D. Constipation: Constipation is not related to hydralazine use or toxicity. This adverse effect is not expected and does not indicate toxicity from the medication.